GCM
SMMT icon

Gunpowder Capital Management’s Summit Therapeutics SMMT Stock Holding History

Gunpowder Capital Management’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-200
Closed -$3.5K – 438
2025
Q4 		$3.5K Buy
+200
New +$3.76K ﹤0.01% 341

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Gunpowder Capital Management's SMMT Position: Q1 2026 in Review

Gunpowder Capital Management sold out of Summit Therapeutics (SMMT) in Q1 2026, closing a stake of 200 shares — an estimated $3.5K sold.

Gunpowder Capital Management first reported a position in SMMT in Q4 2025 and held it in 1 quarter. The position peaked at $3.5K in Q4 2025. 222 funds tracked by Wall St. Rank hold SMMT as of Q1 2026.

  • Gunpowder Capital Management reported no remaining Summit Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Gunpowder Capital Management sold 200 Summit Therapeutics shares in Q1 2026, an estimated $3.5K.
  • Gunpowder Capital Management first reported a position in Summit Therapeutics in Q4 2025 and held it in 1 quarter.
  • Gunpowder Capital Management's Summit Therapeutics position peaked at $3.5K in Q4 2025.
  • 222 funds tracked by Wall St. Rank held Summit Therapeutics as of Q1 2026.

Based on Gunpowder Capital Management's 13F filing for Q1 2026, filed 14 May 2026.